Amgen agrees to acquire deCODE Genetics for $415M

12/11/2012 | GenomeWeb Daily News (free registration) · Reuters

Amgen plans to purchase Iceland-based deCODE Genetics, a pioneer in finding genetic risk factors for various diseases, for $415 million in cash, improving its capability to develop better targeted drugs. The deal "fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets, while avoiding investments in programs based on less well-validated targets," CEO Robert Bradway of Amgen said. The acquisition is expected to be finalized before year-end.

View Full Article in:

GenomeWeb Daily News (free registration) · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID